Magenta Medical

Since 2013 / Life Sciences

    CEO

    Prof. Ehud Schwammenthal

    Board Member

    David Israeli, MD


    Magenta Medical has developed a temporary venous catheter-based therapy for hospital-admitted patients with Acute Decompensated Heart Failure (ADHF). Its novel therapeutic principle is aimed at addressing a pathophysiological core element of acute heart failure - renal venous congestion and its deleterious effects on renal and cardiac function.

    The experimental animal data of the device are compelling and in line with a vast and growing body of clinical and experimental evidence supporting the therapeutic concept. The company is moving towards a First-in-Man study early next year, followed by a European Multicentre Trial.

    Heart failure is a pandemic affecting over 26 million people worldwide, among them 6.5-9 million Europeans and more than 5.5 million Americans. The market for heart failure devices is expected to grow to close to $6 billion in the next two years. ADHF is the leading cause of hospitalisation in the EU and the US, placing a heavy burden on patients and society. The annual costs of hospitalisations currently amount to $26 billion in the US alone, and are projected to more than double over the next 15 years.